22:46 , Apr 17, 2019 |  BC Extra  |  Company News

Management tracks: RegenxBio, Verrica, Reagan-Udall Foundation

Gene therapy company RegenxBio Inc. (NASDAQ:RGNX) hired Steve Pakola as SVP and CMO. Pakola was CMO at Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO). Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) terminated the employment of COO Linda Palczuk, effective April 22....
13:36 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Aerpio's Tie2 activator fails diabetic retinopathy trial

Aerpio said twice-daily 15 mg subcutaneous AKB-9778 missed the primary endpoint in the Phase IIb TIME-2b trial to treat moderate-to-severe non-proliferative diabetic retinopathy. AKB-9778 is a tyrosine kinase receptor 2 (Tie2) activator. On the primary...
00:37 , Dec 22, 2018 |  BC Extra  |  Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

Gossamer Bio Inc. (San Diego, Calif.) plans to raise up to $264.5 million in an IPO on NASDAQ, according to a Dec. 21 SEC filing. The company was launched by ex-Receptos Inc. executives in January...
23:26 , Nov 13, 2018 |  BC Extra  |  Company News

Management tracks: Anchiano, ContraFect

Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc. (OTCQB:ARPO). Anchiano also named Robert Connelly a director. He was a venture partner at Flagship Pioneering and...
18:11 , Jul 27, 2018 |  BC Week In Review  |  Financial News

With Ex-Receptos execs at helm, Gossamer raises another large round

Gossamer Bio Inc. (San Diego, Calif.) raised $230 million on July 23 in an untranched series B round led by new investor Hillhouse Capital, bringing the biotech's total funding to $330 million since its January...
20:21 , Jul 23, 2018 |  BC Extra  |  Financial News

Ex-Receptos team snags another big round at Gossamer

Gossamer Bio Inc. (San Diego, Calif.) raised $230 million in an untranched series B round led by new investor Hillhouse Capital, bringing the biotech's total funding to $330 million since its January launch. Also participating...
00:51 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Bleeding Patient sample and mouse studies suggest HIF1A stabilizers could help treat heavy menstrual bleeding. In endometrial samples from patients, levels of HIF1A were lower than in patients with normal menstrual bleeding. In a...
23:25 , Nov 15, 2017 |  BC Extra  |  Company News

Management tracks: Outpost, Torque

Genitourinary play Outpost Medicine LLC (Indianapolis, Ind.) named Scott Byrd president and CEO. He succeeds interim CEO David Socks, who will remain on the company's board. Byrd was president and COO at the Acacia Pharma...
20:46 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Invirsa raises $520K in seed round

Infectious disease play Invirsa Inc. (Columbus, Ohio) raised $520,000 in a seed financing led by CincyTech. Initial investor Rev1 Ventures also participated. Invirsa's lead candidate, INV-102, is in preclinical testing to treat acute conjunctivitis and...
16:50 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Glaucoma Mouse studies suggest activating Tie2 could help treat primary open-angle glaucoma (POAG). In a mouse model of POAG, intraocular injection of a Tie2-activating antibody decreased intraocular pressure compared with a control antibody. Next...